Hodgkin lymphoma| Volume 110, ISSUE 3, P441-447, March 2014

Download started.


Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy

Published:November 04, 2013DOI:



      To evaluate dose plans for head and neck organs at risk (OARs) for classical Hodgkin lymphoma (HL) patients using involved node radiotherapy (INRT) delivered as 3D conformal radiotherapy (3DCRT), volumetric modulated arc therapy (VMAT), and intensity modulated proton therapy (PT), in comparison to the past mantle field (MF).

      Materials and methods

      Data from 37 patients with cervical lymph node involvement were used. All patients originally received chemotherapy followed by 3DCRT–INRT (30.6 Gy). A VMAT–INRT, PT–INRT (both 30.6 Gy), and a MF plan (36 Gy) were simulated. Doses to head and neck OARs were compared with cumulative DVHs and repeated measures ANOVA.


      The estimated median mean doses were 15.3, 19.3, 15.4, and 37.3 Gy (thyroid), 10.9, 12.0, 7.9, and 34.5 Gy (neck muscles), 2.3, 11.1, 1.8, and 37.1 Gy (larynx), 1.7, 5.1, 1.3, and 23.8 Gy (pharynx), 0.5, 0.8, 0.01, and 32.3 Gy (ipsilateral parotid), and 2.4, 3.8, 0.7, and 34.7 Gy (ipsilateral submandibular) with 3DCRT, VMAT, PT, and MF (all p < 0.0001), respectively.


      The use of INRT significantly lowered the estimated radiation dose to the head and neck OARs. VMAT appeared suboptimal compared to 3DCRT and PT, and for some patients, PT offered an additional gain.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Eich H.T.
        • Diehl V.
        • Gorgen H.
        • et al.
        Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
        J Clin Oncol. 2010; 28: 4199-4206
        • Engert A.
        • Plutschow A.
        • Eich H.T.
        • et al.
        Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma.
        N Engl J Med. 2010; 363: 640-652
        • Engert A.
        • Schiller P.
        • Josting A.
        • et al.
        Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group.
        J Clin Oncol. 2003; 21: 3601-3608
        • Girinsky T.
        • van der Maazen R.
        • Specht L.
        • et al.
        Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines.
        Radiother Oncol. 2006; 79: 270-277
        • Chera B.S.
        • Rodriguez C.
        • Morris C.G.
        • et al.
        Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin’s lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.
        Int J Radiat Oncol Biol Phys. 2009; 75: 1173-1180
        • Fiandra C.
        • Filippi A.R.
        • Catuzzo P.
        • et al.
        Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations.
        Radiat Oncol. 2012; 7: 186
        • Koeck J.
        • Abo-Madyan Y.
        • Lohr F.
        • et al.
        Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
        Int J Radiat Oncol Biol Phys. 2012; 83: 268-276
        • Lu N.N.
        • Li Y.X.
        • Wu R.Y.
        • et al.
        Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin’s lymphoma with mediastinal involvement.
        Int J Radiat Oncol Biol Phys. 2012; 84: 210-216
        • Maraldo M.V.
        • Brodin N.P.
        • Aznar M.C.
        • et al.
        Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
        Ann Oncol. 2013; 24: 2113-2118
        • Weber D.C.
        • Peguret N.
        • Dipasquale G.
        • et al.
        Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.
        Int J Radiat Oncol Biol Phys. 2009; 75: 1578-1586
        • Maraldo M.V.
        • Aznar M.C.
        • Vogelius I.R.
        • et al.
        Involved node radiation therapy: an effective alternative in early-stage Hodgkin lymphoma.
        Int J Radiat Oncol Biol Phys. 2013; 85: 1057-1065
        • Maraldo M.V.
        • Brodin N.P.
        • Vogelius I.R.
        • et al.
        Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma.
        Int J Radiat Oncol Biol Phys. 2012; 83: 1232-1237
      1. Special considerations regarding absorbed-dose and dose–volume prescribing and reporting in IMRT.
        J ICRU. 2010; 10: 27-40
        • Nutting C.M.
        • Morden J.P.
        • Harrington K.J.
        • et al.
        Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
        Lancet Oncol. 2011; 12: 127-136
        • Bethge W.
        • Guggenberger D.
        • Bamberg M.
        • et al.
        Thyroid toxicity of treatment for Hodgkin’s disease.
        Ann Hematol. 2000; 79: 114-118
        • Constine L.S.
        • Donaldson S.S.
        • McDougall I.R.
        • et al.
        Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease.
        Cancer. 1984; 53: 878-883
        • Hancock S.L.
        • Cox R.S.
        • McDougall I.R.
        Thyroid diseases after treatment of Hodgkin’s disease.
        N Engl J Med. 1991; 325: 599-605
        • Bucher J.A.
        • Fleming T.J.
        • Fuller L.M.
        • et al.
        Preliminary observations on the effect of mantle field radiotherapy on salivary flow rates in patients with Hodgkin’s disease.
        J Dent Res. 1988; 67: 518-521
        • Rodrigues N.A.
        • Killion L.
        • Hickey G.
        • et al.
        A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation.
        Int J Radiat Oncol Biol Phys. 2009; 75: 1079-1083
        • van Leeuwen-Segarceanu E.M.
        • Dorresteijn L.D.
        • Pillen S.
        • et al.
        Progressive muscle atrophy and weakness after treatment by mantle field radiotherapy in Hodgkin lymphoma survivors.
        Int J Radiat Oncol Biol Phys. 2012; 82: 612-618
        • Paumier A.
        • Ghalibafian M.
        • Beaudre A.
        • et al.
        Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma.
        Int J Radiat Oncol Biol Phys. 2011; 80: 199-205